Summary

Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

The purpose of this study is to evaluate whether virus-specific T cell lines (VSTs) are safe and can effectively control three viruses (EBV, CMV, and adenovirus) in patients who have had a stem cell transplant and also in patients that have a primary immunodeficiency disorder with no prior stem cell transplant.

Official Title

Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701

Details

Keywords

Cytomegalovirus Infections, Adenovirus Infection, EBV Infection, Hematopoietic Stem Cell Transplant, Primary Immune Deficiency Disease, Infections, Communicable Diseases, Adenoviridae Infections, Epstein-Barr Virus Infections, Virus Specific T-cell (VST) infusion, Virus specific T cell lines (VSTs) against three viruses

Eligibility

Locations

  • UCSF Medical Center
    San Francisco California 94123 United States
  • Stanford Lucile Packard Children's Hospital
    Palo Alto California 94304 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Michael Pulsipher, MD
ID
NCT03475212
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 60 study participants
Last Updated